Abbott Laboratories ( (ABT) ) has released its Q4 earnings. Here is a breakdown of the information Abbott Laboratories presented to its investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Abbott Laboratories is a global healthcare company that develops a wide range of products in diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries. Abbott Laboratories reported a strong financial performance for the fourth quarter and full year of 2024, with a noticeable increase in sales and earnings per share. The company achieved a fourth-quarter sales growth of 7.2% and a full-year sales growth of 4.6%, driven by robust organic growth in its core business areas. The company’s Medical Devices and Nutrition sectors saw significant growth, with Medical Devices achieving a 13.7% increase in quarterly sales. Abbott’s Diagnostics segment also performed well, excluding the impact of decreased COVID-19 testing sales. For 2025, Abbott projects organic sales growth of 7.5% to 8.5% and aims for an adjusted operating margin increase. The company continues to focus on innovation, having announced over 15 new growth opportunities from its R&D pipeline. Abbott’s management expects to maintain its growth trajectory into 2025, supported by strong market positions and a focus on strategic product development.
